Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27890046 | 0.85 | HSP90AB1 (0.43) | HSP90AB1KMT2AL3MBTL1GAAPOLB | |
| SCHEMBL22614748 | 0.82 | HSP90AB1 (0.47) | HSP90AB1HPGDKMT2AL3MBTL1GAA | |
| SCHEMBL14799647 | 0.82 | HSP90AB1 (0.47) | HSP90AB1HPGDKMT2AL3MBTL1GAA | |
| SCHEMBL27306343 | 0.82 | HSP90AB1 (0.67) | HSP90AB1KMT2AGAAPOLBMAPT | |
| SCHEMBL7534898 | 0.82 | HSP90AB1 (0.67) | HSP90AB1HPGDKMT2AGAAPOLB | |
| SCHEMBL30863507 | 0.82 | HSP90AB1 (0.67) | HSP90AB1HPGDKMT2AGAAPOLB | |
| SCHEMBL1922044 | 0.82 | HSP90AB1 (0.47) | HSP90AB1KMT2AGAAPOLBMAPT | |
| SCHEMBL4000497 | 0.82 | GSK3B (0.52) | HPGDKMT2AL3MBTL1GAAMAPT | |
| SCHEMBL9040421 | 0.81 | KDM4E (0.47) | HSP90AB1HPGDKMT2AL3MBTL1GAA | |
| SCHEMBL5952920 | 0.81 | F2R (0.48) | HSP90AB1L3MBTL1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632130-A | Oxadiazole compound and application thereof to preparation of medicament for preventing and/or treating type 2 diabetes | 中国科学院海洋研究所 | 2017-05-10 | — | — | CN | disclosed |
| CN-105801571-A | Heterocyclic difluoromethylated oxirane compound and preparation method thereof | 上海大学 | 2016-07-27 | — | — | CN | disclosed |
| CN-105164125-A | 2-phenyl or 2-heteroaryl imidazo [1, 2-a ] pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-16 | — | — | CN | disclosed |
| CN-105164113-A | Pyrroloamide inhibitors | ABBVIE INC | 2015-12-16 | — | — | CN | disclosed |
| CN-104860931-A | Hepatitis C virus inhibitors and pharmaceutical uses thereof | CHANGZHOU YINSHENG PHARMACEUTICAL CO LTD | 2015-08-26 | — | — | CN | disclosed |
| CN-104349865-A | Solder paste | MITSUBISHI MATERIALS CORP | 2015-02-11 | — | — | CN | disclosed |
| CN-102803249-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-09-10 | — | — | CN | disclosed |
| CN-103370318-A | Substituted imidazopyridazines | BAYER IP GMBH | 2013-10-23 | — | — | CN | disclosed |
| CN-103347878-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-10-09 | — | — | CN | disclosed |
| CN-103249730-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-14 | — | — | CN | disclosed |
| EP-1244649-B1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2005-03-02 | — | — | EP | disclosed |
| CN-1554767-A | Process for preparing chiral medicine intermediate (R)-2-halogen-1-(substituted phenyl) ethanol | 天津南开戈德集团有限公司 | 2004-12-15 | — | — | CN | disclosed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | disclosed |
| US-6444671-B1 | INFLAMMATORY DISEASES, DISEASES WITH ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; INDAZOLES; (1S)-1-((3S,4S)-4-(1-CYCLOPENTYL-3-ETHYL(1H-INDAZOL-6-YL))-3-METHYL-1 -BENZYLPYRROLIDIN-3-YL) ETHAN-1-OL | ICOS CORPORATION | 2002-09-03 | — | — | US | disclosed |
| CN-1358123-A | Solder paste, soldering method using said solder paste and jointed product prepared by said soldering method | SHOWA DENKO KK (JP) | 2002-07-10 | — | — | CN | disclosed |
| US-20020044963-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION, A WASHINGTON CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6362213-B1 | ANTIINFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | ICOS CORPORATION | 2002-03-26 | — | — | US | disclosed |
| CN-1067999-C | Anti-helicobacter heterocyclic derivatives of azolines | JANSSEN PHARMACEUTICA NV (BE) | 2001-07-04 | — | — | CN | disclosed |
| CN-1152310-A | Anti-helicobacter heterocyclic derivatives of azolines | JANSSEN PHARMACEUTICA NV (BE) | 1997-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020044963-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | HSP90AB1 1306/4885HPGD 235/4885KMT2A 3905/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | HSP90AB1 1223/4885HPGD 924/4885KMT2A 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.